The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
The Goodman Cancer Research Centre of McGill University, Montreal, Quebec, Canada.
PLoS Genet. 2019 Aug 30;15(8):e1008344. doi: 10.1371/journal.pgen.1008344. eCollection 2019 Aug.
Pancreatic adenocarcinoma (PC) is a lethal malignancy that is familial or associated with genetic syndromes in 10% of cases. Gene-based surveillance strategies for at-risk individuals may improve clinical outcomes. However, familial PC (FPC) is plagued by genetic heterogeneity and the genetic basis for the majority of FPC remains elusive, hampering the development of gene-based surveillance programs. The study was powered to identify genes with a cumulative pathogenic variant prevalence of at least 3%, which includes the most prevalent PC susceptibility gene, BRCA2. Since the majority of known PC susceptibility genes are involved in DNA repair, we focused on genes implicated in these pathways. We performed a region-based association study using the Mixed-Effects Score Test, followed by leave-one-out characterization of PC-associated gene regions and variants to identify the genes and variants driving risk associations. We evaluated 398 cases from two case series and 987 controls without a personal history of cancer. The first case series consisted of 109 patients with either FPC (n = 101) or PC at ≤50 years of age (n = 8). The second case series was composed of 289 unselected PC cases. We validated this discovery strategy by identifying known pathogenic BRCA2 variants, and also identified SMG1, encoding a serine/threonine protein kinase, to be significantly associated with PC following correction for multiple testing (p = 3.22x10-7). The SMG1 association was validated in a second independent series of 532 FPC cases and 753 controls (p<0.0062, OR = 1.88, 95%CI 1.17-3.03). We showed segregation of the c.4249A>G SMG1 variant in 3 affected relatives in a FPC kindred, and we found c.103G>A to be a recurrent SMG1 variant associating with PC in both the discovery and validation series. These results suggest that SMG1 is a novel PC susceptibility gene, and we identified specific SMG1 gene variants associated with PC risk.
胰腺导管腺癌(PC)是一种致命的恶性肿瘤,在 10%的病例中为家族性或与遗传综合征相关。针对高危个体的基于基因的监测策略可能会改善临床结局。然而,家族性 PC(FPC)受到遗传异质性的困扰,并且大多数 FPC 的遗传基础仍然难以捉摸,这阻碍了基于基因的监测计划的发展。该研究旨在确定累积致病性变异患病率至少为 3%的基因,其中包括最常见的 PC 易感性基因 BRCA2。由于大多数已知的 PC 易感性基因都参与 DNA 修复,因此我们专注于涉及这些途径的基因。我们使用混合效应评分检验进行了基于区域的关联研究,然后对与 PC 相关的基因区域和变体进行逐一分析,以确定驱动风险关联的基因和变体。我们评估了来自两个病例系列的 398 例病例和 987 例无癌症个人史的对照。第一个病例系列包括 109 例 FPC 患者(n = 101)或 50 岁以下 PC 患者(n = 8)。第二个病例系列由 289 例未选择的 PC 病例组成。我们通过鉴定已知的致病性 BRCA2 变体验证了这种发现策略,并且还鉴定了编码丝氨酸/苏氨酸蛋白激酶的 SMG1,在经过多重测试校正后,它与 PC 显著相关(p = 3.22x10-7)。SMG1 关联在第二个独立的 532 例 FPC 病例和 753 例对照系列中得到验证(p<0.0062,OR = 1.88,95%CI 1.17-3.03)。我们在一个 FPC 家系的 3 名受影响亲属中显示了 c.4249A>G SMG1 变体的分离,并且我们发现 c.103G>A 是在发现和验证系列中与 PC 相关的复发性 SMG1 变体。这些结果表明 SMG1 是一种新的 PC 易感性基因,并且我们鉴定了与 PC 风险相关的特定 SMG1 基因变体。